Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway

Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), is the only approved TKI that is effective against T315I mutations in patients with chronic myeloid leukemia (CML). Specific activation of Notch signaling in CML cells by ponatinib can be considered as the “on-target effect” on the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Madonna, Rosalinda, Pieragostino, Damiana, Cufaro, Maria Concetta, Doria, Vanessa, Del Boccio, Piero, Deidda, Martino, Pierdomenico, Sante Donato, Dessalvi, Christian Cadeddu, De Caterina, Raffaele, Mercuro, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141219/
https://www.ncbi.nlm.nih.gov/pubmed/32197359
http://dx.doi.org/10.3390/jcm9030820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141219/
https://www.ncbi.nlm.nih.gov/pubmed/32197359
http://dx.doi.org/10.3390/jcm9030820

Ejemplares similares